Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

WHO recommends clinical trial of Ervebo vaccine in DR Congo

9 August 2026 · By · Wire by Fusion42

Published

9 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

Democratic Republic of the Congo

◆ Source

Read at bastillepost.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

The World Health Organization has recommended a clinical trial of the Ervebo vaccine in the Democratic Republic of the Congo to address the rapidly spreading Ebola outbreak driven by the Bundibugyo virus. The trial aims to protect vulnerable populations in Ebola hotspots, including children and pregnant women, as the current outbreak severely disrupts healthcare services.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You must act now if your business touches epidemic response or vaccine distribution in Africa. The DRC opening for Ervebo trials means fast-tracked vaccine deployment and a new market for solutions addressing outbreak healthcare challenges.

◆ Coverage

1 source · 9 Aug 2026

◆ Related on Wire

◆ Topics

Healthebolavaccine-trialWHODRChealthcare-disruption